Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
D000818:Animals; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D002478:Cells, Cultured; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D009963:Orotic Acid / Q000652:urine; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology; D011742:Pyrimidine Nucleotides / Q000378:metabolism*; D011743:Pyrimidines / Q000096:biosynthesis*; D012263:Ribonucleosides / Q000494:pharmacology; D014529:Uridine / Q000031:analogs & derivatives / Q000652:urine
D009943:Organophosphorus Compounds; D011720:Pyrazoles; D011742:Pyrimidine Nucleotides; D011743:Pyrimidines; D012263:Ribonucleosides; D001224:Aspartic Acid; D009963:Orotic Acid; C013195:sparfosic acid; D010746:Phosphonoacetic Acid; D014529:Uridine